A clinical study of Safflower Yellow injection in treating coronary heart disease angina pectoris with Xin-blood stagnation syndrome

Zhang Qiong; Peng Jian-hua; Zhang Xiang-nong

doi:10.1007/BF02836509

Your Location：

Home >

Browse articles >

A clinical study of Safflower Yellow injection in treating coronary heart disease angina pectoris with Xin-blood stagnation syndrome

Updated：2021-08-27

- A clinical study of Safflower Yellow injection in treating coronary heart disease angina pectoris with Xin-blood stagnation syndrome
- Chinese Journal of Integrative Medicine Vol. 11, Issue 3, Pages: 222-225(2005)
- Affiliations：
  
  1. The National Clinical Base of Drug Research, Xiyuan Hospital, China Academy of Traditional Chinese Medicine,Beijing
  2. Deyuantang Pharmaceutical Ltd. Co., Shangxi
  3. People’s Hospital of Qingdao,China
- Author bio：
- Funds：
  
  Supported by the National High Technology Research and Development Program of China (863 Program), No. 2004AA2Z3692
- DOI：10.1007/BF02836509
  CLC：
- Published：2005，
Scan for full text
Qiong, Z., Jian-hua, P. & Xiang-nong, Z. A clinical study of Safflower Yellow injection in treating coronary heart disease angina pectoris with Xin-blood stagnation syndrome., Chin. J. Integr. Med. 11, 222–225 (2005). https://doi.org/10.1007/BF02836509

Zhang Qiong, Peng Jian-hua, Zhang Xiang-nong. A clinical study of Safflower Yellow injection in treating coronary heart disease angina pectoris with Xin-blood stagnation syndrome. [J]. Chinese Journal of Integrative Medicine 11(3):222-225(2005)
Qiong, Z., Jian-hua, P. & Xiang-nong, Z. A clinical study of Safflower Yellow injection in treating coronary heart disease angina pectoris with Xin-blood stagnation syndrome., Chin. J. Integr. Med. 11, 222–225 (2005). https://doi.org/10.1007/BF02836509 DOI：

Zhang Qiong, Peng Jian-hua, Zhang Xiang-nong. A clinical study of Safflower Yellow injection in treating coronary heart disease angina pectoris with Xin-blood stagnation syndrome. [J]. Chinese Journal of Integrative Medicine 11(3):222-225(2005) DOI： 10.1007/BF02836509.

摘要

Objective: To evaluate the clinical effect and safety of Safflower Yellow injection (SYI) in treating coronary heart disease angina pectoris (CHD-AP) with Xin-blood stagnation syndrome (XBSS).Methods: Adopted was the multi-centered

randomized

positive parallel controlled method

448 patients with CHD-AP-XBSS were enrolled and divided into two groups

336 in the tested group treated with SYI and 112 in the control group treated with Salvia injection by intravenous dripping once a day for 14 days

so as to observe the conditions of angina

electrocardiogram

and therapeutic effect on traditinal Chinese medicine (TCM) symptoms as well as the safety of the treatment.Results: The significantly effective rate and total effective rate in the tested group were 60.06% (194/323) and 91.02% (294/323) respectively; those in improvement of TCM symptoms were 40.18% (129/321) and 75. 23% (243/323) respectively

which were better than those in the control group (P<0.01).Conclusion: SYI Injection is effective and safe in treating CHD-AP-XBSS.

Abstract

randomized

positive parallel controlled method

448 patients with CHD-AP-XBSS were enrolled and divided into two groups

336 in the tested group treated with SYI and 112 in the control group treated with Salvia injection by intravenous dripping once a day for 14 days

so as to observe the conditions of angina

electrocardiogram

which were better than those in the control group (P<0.01).Conclusion: SYI Injection is effective and safe in treating CHD-AP-XBSS.

关键词

Safflower yellow injectioncoronary heart disease angina pectorisXin-Blood stagnation syndrome

Keywords

Safflower yellow injectioncoronary heart disease angina pectorisXin-Blood stagnation syndrome

references

Zheng XY. Guiding principle of clinical research on Chinese new drugs. 1st ed. Beijing: Chinese Publishing of Medical and Pharmaceutical Technique, 2002: 69–73.

Special Group of Clinical Nomenclature Standardization, International Association of Heart Diseases and WHO. Standard for nomenclature and diagnosis of ischemic heart disease. Chin J Cardiol 1981; 9(1): 75–76.

National Administration of Drugs Supervising and Managing. Technologic requirement for research of Chinese new drugs. 2000: 29–30.

Zheng QS, Sun RY, Chen ZY. Safety analysis on the regulation of minimal cases in clinical trial of new drugs. Chin J Clin Pharmacol Ther 2003; 8 (3): 354–355.

Zheng QS, Sun RY, Chen ZY. Discussion on the concise calculation and equivalent standard for sample assessment in new drug clinical trial. Chin New Drug J 2003;12 (5): 368–371.

FULL TEXT LINK

More>

Views

364

Downloads

CSCD

Alert me when the article has been cited

Submit

Tools

Publicity Resources

Thinking on how to construct the system of Chinese medicine efficacy evaluation for coronary heart disease angina pectoris

Clinical non-inferiority trial on treatment of coronary heart disease angina pectoris of Xin-blood stasis syndrome type with lyophilized Salvia salt of lithospermic acid powder for injection

Related Author

No data

Related Institution

Department of Cardiology, Guang’anmen Hospital, China Academy of Chinese Medical Sciences

Xiyuan Hospital, China Academy of Chinese Medical Sciences

Affiliated Hospital of Changchun TCM College

Address：1 Caochang, xiyuan, Beijing, People's Republic of China Postal code：100091
Tel：010-62886827, 62877592 Fax：010-62874291
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备05067934号-1 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰